|

Futibatinib Clinical Trials

5 actively recruiting trials across 2 locations

Also known as: Lytgobi, TAS-120, Tas-120

Pipeline

Phase 2: 3Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Yuanquan Yang1
  • Vall d'Hebron Institute of Oncology1
  • UNICANCER1
  • Gustave Roussy, Cancer Campus, Grand Paris1
  • American Society of Clinical Oncology1

Indications

  • Cancer5
  • Stage IIIA Bladder Cancer AJCC v81
  • Stage II Bladder Cancer AJCC v81
  • Bladder Urothelial Carcinoma1
  • Biliary Tract Neoplasms1

Other3 trials

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3

Birmingham, Alabama1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Ann Arbor, Michigan1 trial

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

University of Michigan Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.